jRCT2031240734招募中不适用
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1-or IDH2-mutant glioma (Vorasidenib in combination with temozolomide (TMZ) in IDH-mutant glioma)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 12age old over 至 No limit（—）
- 性别
- All
入选标准
- •Males or non-pregnant and non-lactating females aged 12 years or older with a weight of 40 kg or more at screening.
- •Have documented IDH1 or IDH2 mutation based on local testing of tumor tissue by an accredited laboratory.
- •Have adequate renal, bone marrow and hepatic function.
- •KPS or LPPS of 70 or higher at the start of study treatment.
- •Additional Inclusion Criteria for Phase 1b:
- •Have histologically confirmed Grade 2, 3 or 4 IDHm (as per WHO 2021) glioma (astrocytoma or oligodendroglioma).
- •Are appropriate to receive TMZ as post- RT adjuvant therapy or as treatment for first disease recurrence after prior RT and/or chemotherapy, per Investigator judgment.
- •Additional Inclusion Criteria for Phase 2:
- •Have histologically confirmed Grade 4 astrocytoma, IDHm (per 2021 WHO criteria).
- •Have absence of 1p19q co-deletion (i.e., non-co-deleted, or intact) and/or documented loss of nuclear ATRX expression or ATRX mutation by local testing.
- •Have received SOC RT with concurrent TMZ (RT-TMZ) before enrollment.
排除标准
- •Unable to swallow oral medication.
- •Are participating in another interventional study at the same time; participation in non-interventional registries or epidemiological studies is allowed.
- •Have leptomeningeal disease.
- •Have a known coagulopathy.
- •Have a known diagnosis of replication repair-deficient glioma (e.g., a known diagnosis of constitutional mismatch repair deficiency or Lynch syndrome).
- •Have significant active cardiac disease within 6 months before Screening, including New York Heart Association Class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke.
- •Have a heart rate corrected QT interval (using Fridericia's formula) (QTcF) 450 msec or higher or have other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).
- •Have known active hepatitis B (HBV) or hepatitis C (HCV) infections, known positive human immunodeficiency virus (HIV) antibody results, or acquired immunodeficiency syndrome (AIDS)-related illness. Participants with a sustained viral response to HCV treatment or immunity to prior HBV infection, or chronic HBV or HIV that are adequately suppressed per institutional practice will be permitted.
- •Have known active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band, dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally. Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential).
- •Additional Exclusion Criteria for Phase 2:
- •Have received any other glioma-directed therapy other than surgery and SOC RT TMZ.
- •Have progressive disease during RT-TMZ or after completion of SOC RT-TMZ and before the start of study treatment.
结局指标
主要结局
-
DLTs (for Phase 1b only), incidence and severity of AEs, SAEs, and AESIs PFS status at 12 months
次要结局
- clinical benefit
- Plasma concentrations
- PK parameters
研究者
相似试验
进行中（未招募）
1 期
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant GliomaIDH1-mutant GliomaIDH2-mutant GliomaNCT06478212Institut de Recherches Internationales Servier51
进行中（未招募）
3 期
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationNCT06780930Servier57
进行中（未招募）
不适用
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)NCT06969352Servier (Tianjin) Pharmaceutical Co. LTD.62
尚未招募
Unknown
Phase 1b/2 trial for venadaparib in combination with paclitaxel and ramucirumab as a second-line therapy for gastric cancer with homologous recombination repair deficiencyNeoplasmsKCT0009067ational Cancer Center75
进行中（未招募）
1 期
Vorinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Relapsed Refractory Multiple MyelomaRelapsed myeloma.MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2011-005361-20-GBniversity of Leeds68